The third phase of the Covaxin trial showed an 81% efficacy against COVID-19 while its vaccine-induced antibodies could neutralize the UK variant.
A statement from Bharat Biotech, which developed the vaccine in collaboration with the Indian Council of Medical Research (ICMR), noted that the data generated involved 25,800 participants between 18-98 years of age, including 2,433 over the age of 60 and 4,500 with comorbidities.
Further, an analysis from the National Institute of Virology indicated that vaccine-induced antibodies could neutralize the UK variant strains and other heterologous strains. The study involved collecting the serum of 38 people who had received the vaccine. The sera were then tested against the UK variant of the virus and a heterologous strain that Covaxin was previously tested against. It concluded that the results showed similar efficacy, and the vaccine could be expected to work against the new UK-variant.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.